Member Contact: David Haylock
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, based in Melbourne, Victoria. VivaZome was formed to develop and commercialise exosome-based therapies, with a focus on treatments for debilitating and/or life-threatening disorders which are not adequately managed by current therapies.
VivaZome plans to work in collaboration to develop new technologies, generate intellectual property and progress the exosome therapies through clinical trials and manufacturing with the aim of providing new effective treatments for Australia and for international markets.
The VivaZome team has significant expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.
Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.
27 August, 2019; Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the execution of a collaborative research and option agreement to explore gene-editing of cells for enhanced exosome production.
Under the agreement, ToolGen will use its CRISPR/Cas9 technology to introduce gene edits into selected cell types. The gene edits are aimed at selectively altering the content and characteristics of exosomes produced by the cells. The gene-edited cells and exosomes will be analysed by VivaZome via its Cooperative Research Centre (CRC)-P partner, La Trobe University.
CRISPR/Cas9 technology allows scientists to insert or delete genes with high efficiency and fidelity. ToolGen is a leading company in the gene editing field and holds CRISPR/Cas9-related patents and patent applications in multiple territories. The agreement includes an option for VivaZome to license ToolGen’s technology, as well as any IP arising from the research program, for the development and commercialisation of exosome products for human therapy.
VivaZome’s Chief Scientific Officer, Dr David Haylock, stated: “VivaZome is very pleased to be able to access ToolGen’s experience, expertise and technology and apply it to the development of this exciting new class of therapeutics. The program with ToolGen is an ideal complement to the project in our CRC-P.”
Director of ToolGen, Dr Jae young Lee, added: “Exosomes have great therapeutic potential and the field of exosomes is growing rapidly. We look forward to working with the team at VivaZome to develop gene edited cells with the potential to enable and accelerate the development of exosome-based therapies.”
CEO of ToolGen, Jongmoon Kim, commented: “This collaboration agreement with VivaZome further validates the value of our gene editing platform. We are very excited to expand our capabilities in this exciting field of research.”
For further information, contact:
VivaZome Therapeutics Pty Ltd
Dr Ian Nisbet, Chairman
Phone: +61 (0) 431 709 121
Hyunseung Shim, Business Strategy Division, PR Manager
Phone: +82 10 9970 0883